A guide for the use of LibreView digital diabetes platform in clinical practice: Expert paper of the Italian Working Group on Diabetes and Technology.

CGM Continuous glucose monitoring Diabetes management system Flash glucose monitoring Glycaemic variability Hypoglycaemia LibreView Time in range

Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
May 2022
Historique:
received: 13 12 2021
revised: 16 03 2022
accepted: 04 04 2022
pubmed: 12 4 2022
medline: 27 5 2022
entrez: 11 4 2022
Statut: ppublish

Résumé

Wider access to continuous glucose monitoring systems, including flash glucose monitoring, has enabled people with diabetes to achieve lower HbA1c levels and reduce the amount of time they spend in hypoglycaemia or hyperglycaemia, and has improved their quality of life. An International Consensus Panel proposed different target glucose ranges and recommendations according to different ages and situations (adults, young people and children with type 1 or type 2 diabetes, as well as elderly people who are at higher risk of hypoglycaemia, and women with diabetes during pregnancy). In this expert opinion, we interpret the international recommendations in the context of established clinical practice for diabetes care, and propose three different step-by-step algorithms to help the healthcare professionals use the most innovative glucose metrics, including time in glucose ranges, glucose management indicator, coefficient of variation, and ambulatory glucose profile. In detail, we focus on glucose metrics as measured by the FreeStyle Libre system and as visualized on the LibreView digital diabetes platform to support appropriate interpretation of flash glucose monitoring data. This is specifically structured for healthcare professionals and general practitioners who may have a low level of confidence with diabetes technology, with the aim of optimizing diabetes management, ensuring effective use of healthcare resources and to maximise outcomes for people with diabetes.

Identifiants

pubmed: 35405166
pii: S0168-8227(22)00680-5
doi: 10.1016/j.diabres.2022.109867
pii:
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109867

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Sergio Di Molfetta (S)

Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy.

Antonio Rossi (A)

Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.

Roberta Assaloni (R)

Diabetes Unit ASS2 Bassa-Friulana Isontina, Udine, Monfalcone, GO, Italy.

Valentino Cherubini (V)

Department of Women's and Children's Health, G. Salesi Hospital, Ancona, Italy.

Agostino Consoli (A)

Endocrinology and Metabolic Diseases, University of Chieti-Pescara, Chieti, Italy.

Paolo Di Bartolo (P)

AUSL Diabetes Unit Romagna, Ravenna, Italy.

Vincenzo Guardasole (V)

Department of Translational Medical Sciences, University Federico II, Naples, Italy.

Andrea Laurenzi (A)

San Raffaele Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Fortunato Lombardo (F)

Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy.

Claudio Maffeis (C)

Pediatric Diabetes and Metabolic Disorders Unit, Regional Center for Pediatric Diabetes, University City Hospital of Verona, Verona, Italy.

Andrea Scaramuzza (A)

Division of Pediatrics, ASST Cremona, "Ospedale Maggiore di Cremona", Cremona, Italy.

Concetta Irace (C)

Department of Health Science, University Magna Graecia, Catanzaro, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH